Overview

• IDEXX Q3 revenue grows 13%, beating analyst expectations

• EPS for Q3 increased 21% to $3.40

Outlook

• IDEXX raises 2025 revenue guidance to $4.27 bln - $4.3 bln

• Company raises 2025 EPS outlook to $12.81 - $13.01

• IDEXX sees 2025 organic revenue growth of 8.8% - 9.5%

Result Drivers

• INNOVATION STRATEGY - IDEXX attributes strong Q3 revenue growth to execution of its innovation-driven strategy, including over 1,700 IDEXX inVue Dx placements

• CAG DIAGNOSTICS - CAG Diagnostics recurring revenue grew 11% as reported, driven by increased diagnostic frequency and easing clinical visit pressures in the U.S.

• OPERATING MARGIN EXPANSION - Operating margin increased by 100 basis points, supported by productivity initiatives and volume gains in Reference Labs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for IDEXX Laboratories Inc is $720.00, about 12.6% above its October 31 closing price of $629.51

• The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 41 three months ago

Press Release: ID:nBw2w3Gwwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)